Dianthus Therapeutics, Inc. /DE/ 8-K

What Happened

• On May 5, 2026, Dianthus Therapeutics, Inc. announced and furnished a press release reporting the company's financial results for the quarter ended March 31, 2026. The update was submitted under Item 2.02 (Results of Operations and Financial Condition) of Form 8-K.

Key Details

• Filing date: May 5, 2026. Quarter covered: ended March 31, 2026.
• The press release is furnished as Exhibit 99.1 to the Form 8-K.
• The company states the information is being furnished (not “filed”) and therefore is not subject to Section 18 liability or automatically incorporated by reference into other filings.
• Form 8-K was signed by Adam M. Veness, Esq., SVP, General Counsel and Secretary.

Why It Matters

• Quarterly financial results provide updated information on earnings, revenue, cash position and operating trends — key inputs for investors assessing company performance. Because the Form 8-K furnishes (and does not file) the press release, investors should read Exhibit 99.1 for the specific numbers and management commentary to understand any impact on valuation or near-term outlook.